Small cell neuroendocrine cancers. The lung, prostate, ovary. Fast. Violent. They spread before you even notice, turning into the kind of tumors that laugh at standard chemotherapy.
For decades, we haven’t really had new tools to fight them. Not since Dr. Owen Witte was a medical student half a century ago, anyway. Survival stats? Still flatlining.
The culprit is usually a gene called RB. In healthy bodies, RB keeps growth in check. A brake pedal. When these cancers drop that gene, the cars fly off the cliff. They multiply wildly. They shrug off targeted therapies like rain.
But here’s the twist.
A new study in PNAS suggests that losing RB creates a weakness. A dependency so strong the cancer can’t live without it.
Finding the Achilles’ Heel
UCLA researchers figured it out. The cells lacking RB need a protein named E2F3.
It’s called synthetic lethality. Sounds fancy. It’s simple math. Remove RB, the cancer lives. Remove both RB and E2F3, and the cancer dies. The cell becomes hypersensitive to the loss of E2F3 because it lost its usual partner, RB, years ago.
“When I first encountered these tumors… the survival statistics were essentially the same.”
— Dr. Owen N. Witte
That quote stings. It reminds you why we keep trying. Why we don’t just shrug our shoulders at resistant cancer.
Building the Beasts to Break Them
The problem with small cell prostate cancer research has been boring. Bland, inaccurate lab models. If you want to know what breaks a specific enemy, you can’t practice on cardboard cutouts. You need something real.
So Witte’s team built it.
They took normal human prostate cells and messed them up. Intentionally. They knocked out RB. They took out TP53. They introduced five major cancer-causing errors. The result? Organoids. Tissue clumps that look and act like actual small cell prostate cancer when shoved into mice.
Finally, a mirror to the human disease.
The Genetic Hunt
Armed with these better models, the team fired up CRISPR screens. They didn’t just look for one thing. They scanned the genome. Thousands of genes. Trying to see what the cancer cells desperately hoard.
They found 1,400 important genes. A lot of noise. But one signal was screaming.
E2F3.
Across organs. Lung. Prostate. Ovary. All of these fast-moving tumors were chained to this protein.
The team lowered E2F3 in the labs. The tumors stopped dividing. The clusters dissolved. In some cases, the cells just gave up the ghost.
“It’s not that they do the same job,” Witte explained. No em-dash, no drama, just mechanics. They do different jobs that fit together like a key in a lock. Lose one? Fine. Lose the key and change the lock shape? Now nothing fits. The machine jams.
First author Dr. Evan Abt called it a vulnerability hidden in plain sight. “Hard to find otherwise.” Maybe impossible, before the better mouse models existed.
A Shortcut With Existing Pills
Here’s where it gets messy. Or clean? Depending on how you look at it.
There are no drugs approved specifically for E2F3. So, if that’s the enemy, who do we shoot?
The team looked at the plumbing. They found a metabolic pipeline—a way cells build DNA bricks—that involves an enzyme called DHODH.
Block DHODH, and E2F3 levels drop. Tumors shrink.
And get this.
We already have pills for that.
Leflunomide. Teriflunomide. FDA-approved drugs. But they aren’t used for cancer. They’re used for autoimmune diseases like rheumatoid arthritis. Millions of people take them. The safety profiles are written in stone.
Why reinvent the wheel? Repurpose the truck.
“Exciting” doesn’t cover it. Abt was right about that. We can skip ten years of basic safety trials if the mechanism checks out. We could be in the clinic much faster than the usual pharmaceutical grind suggests.
It’s early days. The data is fresh. The biology is complex.
But for the first time in a long time, small cell cancer isn’t just a brick wall.
It has a door.
